Tag: Rosuvastatin

1
Australian High Court Rules Rosuvastatin Low Dose Patent Obvious
2
AstraZeneca Loses Latest Bout Over Rosuvastatin Patents

Australian High Court Rules Rosuvastatin Low Dose Patent Obvious

In an eagerly awaited decision¹ the Australian High Court has upheld a decision of a five judge bench of the Full Federal Court that AstraZeneca’s patent relating to low dosages of rosuvastatin is invalid on the basis that the claims lack an inventive step.

Section 7(3) of the Patents Act 1990 (Act) as it existed at the priority date of Astra Zeneca’s patent imposed a threshold requirement that in order to be considered for assessing inventive step a document must be “ascertained, understood and regarded as relevant” by a person skilled in the art.

Read More

AstraZeneca Loses Latest Bout Over Rosuvastatin Patents

The Full Federal Court of Australia has upheld the first instance judgment of the Federal Court of Australia that the three patents protecting AstraZenica’s rosuvastatin products (marketed as Crestor) are invalid.

In judgment handed down on 12 August 2014, the court unanimously dismissed the appeals by AstraZeneca against generic pharmaceutical companies Apotex Pty Ltd, Watson Pharma Pty Ltd and Ascent Pharma Pty Ltd. Read More

Copyright © 2019, K&L Gates LLP. All Rights Reserved.